Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03527238 · ClinicalTrials.gov registry record · Phase 2
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
A Phase 2 study of Kidney Transplant and Liver Transplant, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 3
- Study locations
NCT03527238 is a Phase 2 study of Kidney Transplant and Liver Transplant that has completed, run by University of Florida. The registered enrollment target is 62 participants, below the 1,896-participant average among 30 other Kidney Transplant trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03527238, a Phase 2 study of Kidney Transplant and Liver Transplant, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 3
- Study locations
Study Summary
Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.
Conditions Studied
Interventions
- DRUG Tacrolimus
- OTHER PPM-based Computation Assisted Drug Dosing
Study Locations (3)
California
- UCLA - Los Angeles
Florida
- UF Health at the University of Florida - Gainesville
Other
- National University of Singapore - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03527238
The ClinicalTrials.gov registry entry for NCT03527238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,896-participant average among 30 other Kidney Transplant trials with a reported enrollment target (97% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 2 interventions - of which Tacrolimus is the first listed.
NCT03527238 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT03527238 about?
NCT03527238 is a clinical study titled "Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine". Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.
What is the current status of trial NCT03527238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2018-09-21. Estimated completion is 2021-08-31.
What conditions does trial NCT03527238 study?
This clinical trial studies the following conditions: Kidney Transplant, Liver Transplant.
What interventions are being tested in trial NCT03527238?
The interventions under investigation include: Tacrolimus (DRUG), PPM-based Computation Assisted Drug Dosing (OTHER).
Who is sponsoring clinical trial NCT03527238?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03527238 being conducted?
This trial has 3 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Advancing Transplantation Outcomes in Children
RECRUITING · Phase 2
-
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
RECRUITING · Phase 2
-
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
RECRUITING · Phase 2
-
Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients
COMPLETED · Phase 2
-
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
COMPLETED · Phase 2
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.